Cariprazine Demonstrated Efficacy in Bipolar Depression and Concurrent Manic Symptoms

MedicalResearch.com Interview with:

Dr. Stephen Stahl MD PhDProfessor of Psychiatry University of California San Diego

Dr. Stahl

Dr. Stephen Stahl MD PhD
Professor of Psychiatry
University of California San Diego 

MedicalResearch.com: What is the background for this study? How does cariprazine differ from other medications for bipolar depression? 

MedicalResearch.com: It is important to note that cariprazine, a dopamine D3-preferring D3/D2 receptor and serotonin 5-HT1A receptor partial agonist, is approved for the treatment of schizophrenia (1.5-6 mg/d) and bipolar mania (3-6 mg/d) in adults. It is not yet approved for depressive episodes related to bipolar I disorder (bipolar depression).

In these data that focus on the investigational use for the treatment of bipolar depression, cariprazine has demonstrated efficacy vs placebo (PBO) in 3 phase 2/3 studies of patients with bipolar depression (NCT01396447, NCT02670538, NCT02670551). These analyses investigated the efficacy of cariprazine in patients with bipolar depression and concurrent manic symptoms (mixed features).  Continue reading